cyrilzakka/clinical-trials huggingface dataset:
Post Covid Syndrome: Clinical Pattern and Functional Assessment

Aim(s) of the Research :

1. Identify post covid symptoms
2. prevalance of post covid syndrome among survivours

There is currently very limited information on the nature and prevalence of post-COVID-19 symptoms after hospital discharge. On 11th March 2020, corona virus disease 2019 (COVID-19) was declared a global pandemic by the World Health Organisation (WHO). Egypt has been one of the worst affected countries with over 101,500 confirmed cases and more than 5,696 confirmed deaths at the time of writing (17/9 2020) .1 COVID-19 is caused by the corona virus SARSCoV-2 and presents with a wide spectrum of clinical symptoms. Wu et al reported that 81% of people with COVID-19 in China presented with mild symptoms; 14% presented with symptoms of severe respiratory dysfunction; and 5% developed a critical illness with respiratory failure, septic shock, and multiple organ dysfunction or failure.2 The medium and long-term problems experienced by survivors of COVID-19 after discharge from hospital are currently unknown, but there is some emerging evidence. An Italian study followed-up 143 individuals 7 weeks post-discharge and found 53% reporting fatigue, 43% breathlessness and 27% joint pain.3 Post-discharge symptoms may also be predicted from the previous coronavirus outbreaks of Severe Acute Respiratory Syndrome (SARS) in 2002 and Middle East Respiratory Syndrome (MERS) in 2012. A meta-analysis of 28 follow-up studies found that one quarter of hospitalised survivors of SARS and MERS had reduced lung function and exercise capacity at six months post-discharge.4 At one year, post-traumatic stress disorder (PTSD), depression and anxiety, and reduced quality of life were observed Specific data concerning the rehabilitation needs of this group is therefore urgently required.

Eligibility Criteria:
Inclusion Criteria:

1. patients diagnosed as covid 19 with chest ct and/or nasopharyngeal swab for covid 19
2. age 18 years old and above
3. post covid syndrome after 6 weeks

Exclusion Criteria:

* 1-below age of 18 2 -not confirmed cases 3. symptoms less than 6 weeks
TECH App Marijuana Use Intervention for Court-Involved Adolescents

The study is about helping teens who are involved in the court system to cut down or quit using marijuana. Teens may be asked to test out an experimental smartphone app, called TECH, that will be used only by teens in this study. This app is a private online community where teens can work towards changing their substance use and other behavior with the help of other anonymous teens. We will use this information to learn how the app may help teens make a change and to improve the TECH app.

This multiphase study will establish the feasibility, acceptability, and preliminary efficacy of a novel smartphone app that leverages both intrapersonal and interpersonal mechanisms to promote cannabis-related behavior change among CINI youth ages 14-17. The app, Teen Empowerment through Computerized Health (TECH), will be evaluated as an adjunct to treatment as usual (TAU) at the local family court. Phase 1 (completed Fall 2021) included a series of semi-structured interviews with key individuals, to inform how clinical goals (e.g., reduced cannabis use) will map onto usage goals (e.g., goal-setting, peer networking), features (e.g., expert-moderated forum, notifications) and workflow. Then, Phase 2 (completed Fall 2022) beta tested and iteratively refined the TECH prototype with 10 court-involved, non-incarcerated (CINI) youth. In the current phase of the work, Phase 3, we will conduct a pilot randomized control trial (RCT) with 60 CINI youth to test the TECH app (TAU+TECH) relative to TAU-only.

Specific aims are:

Aim 1. Apply the Behavior Intervention Theory model to develop a user-driven tool (i.e., TECH) that capitalizes on how, why, and when CINI youth would most prefer to engage with a smartphone app to reduce cannabis use.

\~Aim 1 was achieved in Phase 1 qualitative interviews with CINI youth, their parents, and behavioral health app developers.

Aim 2. Examine the feasibility and acceptability of the TECH user-driven smartphone app.

\~Hypothesis 1 is that TECH will be feasible and acceptable to CINI youth, as measured via enrollment and withdrawal rates, app usage data, and exit interviews. Aim 2 will be achieved through Phase 2 beta testing (n = 10) and Phase 3's pilot RCT (n = 60) with CINI youth.

Aim 3. Test the preliminary efficacy of the TECH smartphone app as an adjunct to TAU (TECH + TAU vs. TAU-only) on cannabis use (primary outcome).

\~Hypothesis 2 is that, relative to CINI youth who receive TAU-only, the TAU+TECH group will demonstrate greater reductions in cannabis use. Aim 3 will be achieved via Phase 3's pilot RCT (n = 60 CINI youth).

Eligibility Criteria:
Inclusion Criteria:

* Aged 14 years to 18 years
* Able to speak and read English
* Have access to a smartphone
* Self-report past-year cannabis use
* If a minor, able to provide parental consent and child assent

Exclusion Criteria for all participants is limited to conditions that would preclude active participation in an intervention study of a mobile app (e.g., psychosis, cognitive impairment, visual impairment).
Weaning And Variability Evaluation (WAVE)

The purpose of this study is to determine if variability in heart and breathing rates can be used to predict successful weaning. We are collecting data to determine whether or not subtle differences in heart rate and respiratory function will help physicians to decide if a patient is ready to be weaned.

In this prospective observational pilot study, mechanically ventilated patients weaning or near extubation (i.e. within 1-5 days) were selected to undergo continuous heart rate (EKG waveform at 500 Hz) and respiratory rate (expired CO2 waveform at 100 Hz) recording. The data was collected as per standard practice by the bedside monitor (Phillips Intelivue MP70). A portable CPU with TrendfaceTM software was used to download the data for variability analysis. All decisions on timing of SBTs and extubation were left to the discretion of the treating team who were unaware of the variability results. SBT's were repeated daily from trial onset until extubation patient permitting.

Eligibility Criteria:
Inclusion Criteria:

* Patients who have been requiring mechanical ventilation for \>48 hours.
* At least partial reversal of the condition precipitating invasive ventilation.
* Stabilization of "other" organ system failures (i.e. no worsening).
* The patient is able to tolerate pressure support ventilation ≤14 cm H2O (SpO2 ≥ 90% with FiO2 ≤ 40% and PEEP ≤ 10 cm H2O)
* The patient is hemodynamically stable (off vasopressors or on low levels of vasopressors).
* Stable neurological status (no deterioration in the last 24 hors, intact respiratory drive and ICP \< 20).
* The patient has intact airway reflexes (adequate cough with suctioning and a gag reflex).

Exclusion Criteria:

* Allergy to skin adhesives or a contraindication to placing electrocardiogram adhesives (e.g. severe psoriasis).
* Do not reintubate order documented on chart or anticipated withdrawal of life support.
* Tracheostomy
* Known or suspected severe myopathy or neuropathy (i.e. myasthenia gravis, Guillain-Barré syndrome) or quadriplegia.
* Severe heart failure or Grade IV left ventricular function.
* Prior extubation during ICU stay.
Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have metastatic germ cell tumors that have not responded to cisplatin.

OBJECTIVES: I. Determine the efficacy of temozolomide in patients with cisplatin refractory metastatic germ cell tumors. II. Determine the safety of this treatment in these patients.

OUTLINE: Patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study over 25 months.

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed metastatic germ cell tumor Seminoma OR Nonseminoma Measurable disease Abnormalities on radiograph OR Alpha fetoprotein greater than 15 ng/mL OR Beta human chorionic gonadotropin greater than 2.2 mIU/L At least one measurable disease site that has not received prior radiotherapy Refractory to prior cisplatin and failed, not eligible for, or refused autologous bone marrow transplantation

PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Karnofsky 70-100% Life expectancy: At least 3 months Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least 1,000/mm3 Platelet count at lest 80,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than 1.5 times normal Transaminases no greater than 1.5 times upper limit or normal (ULN) Alkaline phosphatase no greater than 3.0 times ULN Renal: Creatinine no greater than 1.5 times ULN Other: No medical conditions that would interfere with swallowing or cause excessive vomiting No second malignancy except basal and squamous cell skin cancer Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: Not specified
Effect of Dual-Task Training on Pediatric Oncology Patients

It is known that the treatment of children with cancer has negative effects on cognition, muscle strength, balance, and gait. Therefore, the aim of this study is to evaluate the effects of dual-task training, which is based on the principle of simultaneous performance of cognitive tasks and motor tasks, on muscle strength, balance, and gait.

With the increase in the incidence of cancer, the number of children who survived cancer is also increasing. Most studies on cancer survivors show that the disease and its treatment have side effects and long-term late effects on the musculoskeletal system, physical function, motor, and cognitive skills. Therefore, the aim of this study is to evaluate the effects of dual-task training, which is based on the principle of simultaneous performance of cognitive tasks and motor tasks, on muscle strength, balance, and gait. This study is planned to be the first study in which dual-task training is applied in children with cancer.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with pediatric cancer and inpatient and outpatient treatment in Hematology-Oncology Clinics for treatment,
* Able to walk alone without any walking aid,
* Children aged 6-18 will be included

Exclusion Criteria:

* Staying in an isolated room or at risk of infection (neutropenic, etc.),
* Any orthopedic or neurological disorder that may prevent walking;
* Having any mental disability that will prevent performing a cognitive task,
* Individuals with malignant hypertension or unstable heart disease (eg, congestive heart failure) will not be included in the study.
Evaluation of the Relationship Between Missed Appointments and Adherence to Medical Indications

We will conduct a cross-sectional study involving adults with type 2 diabetes mellitus. Our primary objective is to evaluate the association between nonattendance and participants' adherence to both pharmacological and non-pharmacological medical recommendations, as well as COVID-19 prevention measures. Additionally, we will assess the adherence rates to these medical recommendations, COVID-19 prevention protocols, and the recommended health care practices and controls for patients with type 2 diabetes mellitus.

Non-attendance at outpatient visits and lack of adherence to medical recommendations are prevalent issues that negatively impact the health care system. While tools exist to assess pharmacological adherence, evaluating adherence to non-pharmacological recommendations remains challenging. Some studies suggest using nonattendance as an objective and easily measurable marker of adherence.

The aim of this study is to evaluate the association between nonattendance and adherence to medical recommendations in adults with type 2 diabetes mellitus.

We will conduct a cross-sectional study involving adults with type 2 diabetes mellitus. We will evaluate the association between participants' nonattendance and their adherence to both pharmacological and non-pharmacological medical recommendations, as well as COVID-19 prevention measures. Additionally, we will assess the adherence rates to these recommendations, COVID-19 prevention measures, and the recommended health care practices and controls for patients with type 2 diabetes mellitus.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients (over 18 years old), affiliated with the medical insurance of the Hospital Italiano de Buenos Aires for at least two years.
* Patients with a diagnosis of type 2 diabetes mellitus at least 2 years before the date of entry to the study Will be included.

Exclusion Criteria:

* Refusal to participate or to the informed consent process.
* Difficulties with language or comprehension (includes pathologies that alter the understanding of the indications or compliance with them (dementia, encephalopathy, intellectual disability, psychiatric disorders).
* Recent hospitalization (the month before the phone call).
* Medical follow-up outside of Hospital Italiano de Buenos Aires.
* Work as health personnel.
* Communication failure (wrong phone number or no response to 3 calls on different days and times)
Electroacupuncture vs. Sham Electroacupuncture for Treatment of Fatigue in Patients With Inflammatory Bowel Disease

Fatigue is a common symptom in inflammatory bowel diseaseI and persists despite clinical remission. Fatigue in patients with chronic diseases can be objectified by the FACIT-F scale. Acupuncture has been shown useful in the treatment of fatigue in various chronic diseases.

This study evaluates the effect of electroacupuncture in the treatment of fatigue in patients with quiescent inflammatory bowel disease.

Patients with inflammatory bowel disease and severe fatigue (FACIT-F score \<38) who agree to participate in the study will be randomized to three different treatments: electroacupuncture vs. sham electroacupuncture vs. control group.

Fatigue is a common symptom in inflammatory bowel disease and persists despite clinical remission. Fatigue in patients with chronic diseases can be objectified by the FACIT-F scale. Acupuncture has been shown useful in the treatment of fatigue in various chronic diseases.

This study evaluates the effect of electroacupuncture in the treatment of fatigue in patients with quiescent inflammatory bowel disease.

Patients with inflammatory bowel disease and severe fatigue (FACIT-F score \< 38) who agree to participate in the study will be randomized to three different treatments: electroacupuncture vs. sham electroacupuncture vs. group control.

Treatment consists of a total of 9 sessions / patient (2 sessions / week the first week and then one session / week for two months).

During and after treatment, patients fill in questionnaires to assess fatigue, anxiety, depression, quality of life in inflammatory bowel disease and sleepiness. Those patients who do not improve with the initial treatment or present a recurrence of fatigue (defined as a decrease of at least 4 points in the FACIT-F score) then receive crossover treatment for 8 more weeks (total of 9 new sessions).

The control group fill in questionnaires in the same periods as patients who receive active treatment. These patients (control group) receive electroacupuncture sessions(total of 9 sessions) in a second period.

Eligibility Criteria:
Inclusion Criteria:

* Patients with inflammatory bowel disease and fatigue in patients over 18 years
* Presence of continued fatigue determined in two consecutive scores and stability of the symptoms of fatigue according to the patient's opinion .
* Inflammatory bowel disease diagnosed at least 6 months before the study (diagnosed by clinical, laboratory , endoscopic and histological criteria) .
* Written informed consent

Exclusion Criteria:

* Patients who are participating in other clinical studies.
* Associated tumor disease .
* Pregnant or breast feeding women .
* Anemia Hemoglobin determined under 12 in women and 14 in men.
* Patients who have suffered minor adverse reactions to acupuncture.
* Prior Acupuncture.
Human CNS Tau Kinetics in Tauopathies

The goal of this study is to characterize tau kinetics and tau aggregation in the human CNS and to test the hypothesis that tau kinetics are altered (i.e. increased production, decreased clearance, and increased aggregation rate) in tauopathies.

Tauopathies are neurodegenerative diseases with tau pathology. These tauopathies are the most common pathology in neurodegenerative diseases, and they are reaching epidemic proportions. The rates of tau kinetics are central to understanding normal and abnormal processing and production and clearance of tau kinetics in humans to help understand the causes of tauopathy and evaluate tau-targeted therapeutics.

This study will utilize the Stable Isotope Labeling Kinetics (SILK) method to elucidate tau kinetics in vivo in the human central nervous system (CNS) and its alteration in tauopathies. A total of \~34 participants from 3 different neurodegenerative diseases: Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD), and Progressive Supranuclear Palsy (PSP), will be invited to enroll in the study.

Participants will be labeled with stable isotopes via 16hr intravenous infusion and CSF samples collected during subsequent lumbar puncture visits over \~120 days. CSF will be analyzed over time for the quantitation of labeled tau.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with PSP, CBD, or FTD MAPT

Exclusion Criteria:

* Clotting disorder
* Active anticoagulation therapy
* Active infection
* Meningitis
* Recent syncope
* Current experimental treatment targeting Aβ or medications thought to influence Aβ production or clearance rates (benzodiazepines, muscarinic agents, or anti-epileptics)
PET in Guiding Cervical Lymphadenectomy (ECTOP-2003)

Esophageal cancer is the eighth most common cancer around the world, with more than 450000 new cases per year. Esophagectomy with radical lymphadenectomy (2-field lymphadenectomy) is the mainstay of treatment in many countries for patients with esophageal cancer. To improve the survival, 3-field lymphadenectomy combined with cervical lymphadenectomy was started in 1980s. More potential positive lymph nodes were found during more extended lymphadenectomy, offering more accurate TNM staging, affecting consequent treatment. However，3-field-lymphadenectomy was associated with increased surgical morbidity and mortality. Positron emission tomography (PET) is used for detecting distant metastases and lymphatic involvement. The aim of the study is to evaluate the role of PET in predicting cervical lymph metastases of patients with thoracic esophageal squamous cell carcinoma, and to determine if investigators can use PET to guide future cervical lymphadenectomy. (Eastern Cooperative Thoracic Oncology Projects 2003, ECTOP-2003)

From June, 2018, a total of 110 patients with thoracic esophageal carcinoma will be recruited in 4 hospital in China. Participants with resectable esophageal cancer will have PET/CT scan before three-field lymphadenectomy. Lymph nodes will be recored according to the anatomy site. Lymph nodes metastasis diagnosed by PET/CT and by postoperation pathological examination will be compared to evaluate the role of PET/CT in guiding the extent of lymphadenecomy and surgical approach.

Eligibility Criteria:
Inclusion Criteria:

1. Histologically proven esophageal cancer
2. Resectable cT1-T3/N0-N1 thoracic，operable esophageal lesion. Staging investigations including esophagogastroscopy, chest and abdominal CT scan, and barium swallow
3. Karnofsky performance status greater than or equal to 80%
4. Acceptable pulmonary and cardiac function.
5. Acceptable hepatic, renal and bone marrow function

Exclusion Criteria:

1. Low performance status(Karnofsky score \<80%)
2. Past history of malignancy
3. Unresectable advanced disease(T4 or M1a,M1b)
4. Patients with any other serious underlying medical condition that would impair the ability of the patient to receive or comply with protocol treatment
5. Medically unfit for surgical resection
6. Pulmonary reserve inadequate to undergo thoracotomy and extensive mediastinal lymphadenectomy.
7. A significant history of unstable cardiovascular disease that in the opinion of the treating physician should preclude the patient from protocol treatment.
8. Uncontrolled diabetes mellitus or uncontrolled infection, including HIV or interstitial pneumonia or interstitial fibrosis.
9. Significant psychiatric illness that would interfere with patient compliance
10. Severe hepatic cirrhosis or with serious renal disease unacceptable for surgery
11. Salvage surgery after definitive chemoradiotherapy
12. Patients have neoadjuvant chemoradiotherapy
13. Above the age of 80 years
14. Unreliable for follow up
The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers

In patients with cancer of the head and neck and rectum, knowing the exact location of the tumor is important for designing the radiation field to ensure delivery of high dose of radiation to the tumor while sparing surrounding normal tissues. A new medical imaging method which is a combination of positron emission tomography (PET) and computed tomography (CT) scan, has shown promise in helping the radiation oncologist in defining the exact location and extent of the tumor in certain cancers such as lung cancers. Therefore the purpose of this study is to determine if these imaging methods can be used in combination with the standard radiation treatment planning procedure to improve the accuracy to targeting your tumor with radiation. In addition the PET-CT scan, similar to the PET scan alone with better resolution, can be used to determine whether the tumor has spread to any part of the body outside of the head and neck sites.


Eligibility Criteria:
Inclusion Criteria:Patients who are scheduled to receive radiation therapy for head and neck cancer at Stanford.

Exclusion Criteria:Non-Stanford patients.